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Freeze-drying approach to enhance antibody stability
INTRODUCTION
Preparations containing antibodies are more easily formulated in solution, but their stability is often impaired. Aqueous solutions
are prone to numerous physical and chemical changes, such as denaturation, aggregation, adsorption, hydrolysis,
deamidation, nonreducible cross-linking, formation/exchange of disulfide bonds, isomerization, fragmentation, Maillard-
reaction, etc. Freeze-drying enables preservation of the desired characteristics of the product for a longer period of time, thus
increasing its shelf life.
Part of the challenges associated with the first phase of the freeze-drying process can be addressed with its’ corresponding
design, i.e. defining the freezing rate, but also addition of bulking crystalline agents as mannitol, glycine or disaccharides (sucrose,
trechalose), that can provide fine, microporous structure. Recent research had shown that slow freezing, which includes gradual
cooling of the sample to a given temperature with a certain rate, and fast freezing, including direct introduction of the sample to
a previously cooled freeze-dryer, are the most favored.
METHODS
Anti-CD-20 antibody (rituximab conjugated with 1B4M-
DTPA) was freeze-dried with or without presence of
cryoprotectant mannitol, using stoppering tray freeze dryer
(Labconco Free Zone Stoppering Tray Dryer, USA), Fig 1.
Two types of freeze-drying protocols were applied, Protocol
I, with direct freezing to the initial temperature of -40 °C and
Protocol II, with gradual freezing from 5 °C to -40 °C, at a
rate of 0,40 °C/min. Appearance after reconstitution of the
finished product and presence of aggregates at
wavelength of 410nm were evaluated, as well as the IR and
Raman spectra.
RESULTS
The analysis of the results obtained showed that using gradual
freezing from 5 °C to -40 °C, at a rate of 0,40 °C/min was more
successful in maintaining the stability of the antibody during freeze-
drying (Table 1). The appearance of the formulations after freeze-
drying and reconstitution are given in Fig 2. The formulations that
were freeze-dried using Protocol II gave clear solutions after
reconstitution, no presence of aggregates (lower absorption at 410
nm) and IR and Raman spectra most similar to the spectra of the
native conjugated form (results not shown).
CONCLUSION
The research performed, enabled selection of a freeze-
drying protocol that was most successful in maintaining the
stability of the conjugated Anti-CD-20 in terms of presence
of aggregates and maintenance of antibody structure post-
freeze-drying process.
The obtained results, are in further use for developing a
formulation of ready-to label freeze-dried kits, intended for
preclinical research for Non-Hodgkin’s lymphoma therapy.
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Fig. 2. I) Appearance of rituximab-DTPA-1B4M formulations after 
lyophilization: A) lyophilisate with 10 mg/mL mannitol, Protocol, I; B) 
lyophilisate without mannitol, Protocol I; C) lyophilisate with 10 mg/mL 
mannitol, Protocol II; D ) lyophilisate without mannitol, Protocol II. 
II) Appearance of the same batch after reconstitution.
Table 1. Reconstitution speed ​​of the lyophilized formulations, appearance after
reconstitution and absorbance at 410 nm.
Sample
Reconstitution 
time (s)
A410nm
Clarity after 
reconstitution
Rituximab DTPA-1B4M without 
mannitol, Protocol I
25-40 0.219 Slightly opalescent
Rituximab DTPA-1B4M with 10
mg/mL mannitol, Protocol I
30-45 0.396
Moderately 
opalescent
Rituximab DTPA-1B4M without 
mannitol, Protocol II
30-45 0.225 Slightly opalescent
Rituximab DTPA-1B4M with 10
mg/mL mannitol, Protocol II
50-70 0.474
Moderately 
opalescent
I)
II)
Fig. 1. Labconco Free Zone Stoppering Tray Dryer.
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